Floatz Rating
D30/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
18Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04599634CT.gov Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Magrolimab (this asset) | National Cancer Institute (NCI) | P1 | D · 30 |
| Prednisone | National Cancer Institute (NCI) | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Ruijin Hospital | P4 | BB |
| Cyclophosphamide | Miltenyi Biomedicine GmbH | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| (+)-Vincristine | National Cancer Institute (NCI) | P4 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Magrolimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P3 | CC · 40 |
| Myelodysplastic Syndrome | — | P2 | CC · 40 |
| Non-Hodgkin Lymphoma | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Magrolimab in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/magrolimab-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →